Research & Projects

ESCMID Panorama

ESCMID Study Group for Mycobacterial Infections - ESGMYC

News & Activities

Coming soon

26-28 September 2019, Singapore, Singapore

View the Flyer here

For other ESCMID courses & workshops please refer to this page


December 3-5, 2018, Lille, France

2018 is the 110th anniversary of the first subculture of  'lait de Nocard', the Mycobacterium bovis strain that eventually led to the Bacillus Calmette-Guérin (BCG). 

This first step towards the most widely used vaccine in the world was undertaken at the Institut Pasteur de Lille under the direction of Albert Calmette. We intend to celebrate this important anniversary in the form of an international scientific symposium on all aspects of BCG. 

This symposium will be held from December 3rd to December 5th, 2018 at the Institut Pasteur de Lille, Lille, France and will cover 

- The history of BCG
- The place of BCG in the fight against tuberculosis and other mycobacterial diseases
- Genomics of BCG
- Next generation BCGs
- Off-target effects of BCG
- BCG and cancer, auto-immunity and inflammatory diseases. 

Find out more here.


Management of Mycobacterial infections and Associated Comorbidities

ESCMID Postgraduate Education Course, 27-28 September 2018, Rome, Italy

The aim of this course organized by ESGMYC was to provide participants with an updated insight into tuberculosis and non-tuberculous mycobacterial infections in the increasing susceptible population worldwide. The course developed a detailed understanding of immunopathogenic, clinical, therapeutic and preventive aspects of mycobacterial infections associated with the most common comorbidities. The course was attended by 35 participants from 15 countries, with Faculty from 10 countries including the USA, Belarus and Turkey. More information here.

Global tuberculosis report 2018

WHO has published a global TB report every year since 1997. The main aim of the report is to provide a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease at global, regional and country levels. This is done in the context of recommended global TB strategies and targets endorsed by WHO’s Member States and broader development goals set by the United Nations (UN). The 2018 edition of the global TB report was released on 18 September, in the lead up to the first-ever UN High Level Meeting on TB on 26 September 2018.


Read more and download the report here.


Tuberculosis surveillance and monitoring in Europe, 2017

Overall in 2015 there were an estimated 323 000 new TB cases and relapses in the WHO European Region, with 60 195 cases of TB reported in 30 European Union/European Economic Area (EU/EEA) countries.

Although the EU/EEA notification rate is continuing a long-term decreasing trend, annual rates of decline are still too small to envisage TB elimination in Europe by 2025 and treatment success rates have remained largely unchanged over the past 10 years. One area of particular concern is multidrug-resistant TB and this remains a major challenge for TB control in the WHO European Region.


Read more and download the report here.

To provide an up-to-date overview for management guidance, CMI devotes its March 2017 issue to M/XDR-TB. The state-of-the-art reviews address prevention of M/XDR-TB, management of M/XDR-TB in migrants, the use of novel diagnostic interventions, including whole genome sequencing, and current standards of clinical management to treat patients with M/XDR-TB.

Tuberculosis (TB) is a major cause of morbidity and mortality in Europe. High-quality laboratory diagnosis of TB is the basis for both individual patient treatment and surveillance.

The aim of this handbook is to provide network members and other laboratories involved in the diagnosis of tuberculosis, with an agreed list of key diagnostic methods and their protocols in various areas of TB diagnosis, ranging from microbiological diagnosis of active TB to the diagnosis of latent TB infection. This handbook offers a single source of reference by compiling all methods, with a strong focus on standard (reference) and evidence-based methods. In so doing, it will also contribute to the improvement of disease surveillance data for Europe.

The first version of this report, previously published as ‘Mastering the basics of TB control: Development of a handbook on TB diagnostic methods’ (Stockholm 2011) concerned the development of the handbook which was included as an annex. This report has now been revised, updated and renamed as the ‘Handbook on TB laboratory diagnostic methods for the European Union’.


EUCAST, ESGMYC and EMA recently released the report of a workshop on recommendations for pharmaceutical companies regarding data required for new antituberculous drugs (11-12 November 2014, Basel, Switzerland).


The European Centre for Disease Prevention and Control (ECDC) and the World Health Organization (WHO) Regional Office for Europe launched jointly the fifth report on surveillance and monitoring of tuberculosis (TB) in Europe.

This year’s report highlights two subsets of TB cases that tend to be neglected by routine surveillance: extrapulmonary TB cases (based on data from The European Surveillance System (TESSy) and prisoners with TB (based on Tuberculosis Monitoring and Evaluation (TME) data).

ESCMID PGEC Gaining Expertise on Mycobacterial Infections

Paris, France, May 2013

Course material in the ESCMID OLL


This handbook consists of nine chapters describing basic techniques in the laboratory diagnosis of tuberculosis. It covers biosafety, quality assurance, latent TB infection, smear microscopy, identification of M. tuberculosis and drug resistance, culture, drug susceptibility testing, and molecular methods.
This first edition is intended to contribute to the harmonisation of diagnostic methods for TB within the EU/EEA.

ECDC Handbook

Download the latest Annual Report.